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Abstract: In the present study, a small marine-derived natural products library was assessed for
antibacterial potential. Among 36 isolated compounds, a number of bis-indole derivatives exhibited
growth-inhibitory activity towards Gram-positive strains (Bacillus subtilis and multidrug-resistant
Staphylococcus aureus). 5- and 6-trisindoline (5-Tris and 6-Tris) were the most active derivatives
(minimum inhibitory concentration, MIC, 4–8 µM) that were subsequently selected for anti-biofilm
activity evaluation. Only 5-Tris was able to inhibit the staphylococcal biofilm formation starting at a
5 µM concentration. In order to investigate their possible molecular targets, both natural products
were subjected to in silico inverse virtual screening. Among 20 target proteins, DNA gyrase and
pyruvate kinase were the most likely to be involved in the observed antibacterial and anti-biofilm
activities of both selected natural products. The in vitro validation and in silico binding mode
studies revealed that 5-Tris could act as a dual enzyme inhibitor (IC50 11.4 ± 0.03 and 6.6 ± 0.05 µM,
respectively), while 6-Tris was a low micromolar gyrase-B inhibitor (IC50 2.1 ± 0.08 µM), indicating
that the bromine position plays a crucial role in the determination of the antibacterial lead compound
inhibitory activity.
Keywords: MRSA; trisindoline; antibacterial; antibiofilm; inverse virtual screening; gyrase-B;
pyruvate kinase; marine natural products
1. Introduction
Staphylococci are considered dangerous opportunistic microorganisms, and are associated with
many serious infections, including those that are hospital-acquired. In most cases of staphylococcal
Microorganisms 2020, 8, 293; doi:10.3390/microorganisms8020293 www.mdpi.com/journal/microorganisms
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nosocomial infections, the isolated causative strains were found to be antibiotic-resistant [1–3].
The number of reported multidrug-resistant Staphylococcus aureus and Staphylococcus epidermidis (MRSA
and MRSE, respectively) strains that show resistance against conventional antibiotics (e.g., macrolides
and aminoglycosides) is on the rise. Additionally, their ability to protect themselves within biofilms on
many different surfaces significantly contributes to antibiotic-resistance (i.e., phenotypic resistance) [4].
The limited effectiveness of standard antibiotics in dealing with biofilm-related infections, which
increase the emergence of multidrug-resistant staphylococci, together with the increased dependence on
implanted medical devices, drives the need for exploring and developing new classes of antimicrobials.
Recently, pyruvate kinase (PK) has been identified as a crucial enzyme in staphylococci, and regulates
their growth, antibiotic resistance, and biofilm formation [5–7]. Furthermore, it was found to be
structurally distinct from human homologs, and hence it provides a promising target for novel
antimicrobial agents [8,9]. On the other hand, DNA gyrase is a topoisomerase-type enzyme that
is required during bacterial DNA replication and transcription to maintain topology and integrity.
It consists of four subunits (two A subunits and two B subunits) attached together to form a tetrameric
holoenzyme [10]. Currently, DNA gyrase is considered one of the primary targets and has been clinically
validated in most pathogenic bacteria. Fluoroquinolones are well-known DNA gyrase inhibitors that
target the enzyme’s A subunit specifically. They have achieved great success as antibacterial agents
over the last 20 years; however, a number of resistant strains have emerged recently. Additionally,
they are more active towards the Gram-negative bacteria in comparison with Gram-positive ones
such as S. aureus and S. epidermidis [11]. Many research groups worldwide are focusing on the
development of novel antibacterial drugs by targeting DNA gyrase B subunits [12–14]. Besides their
bactericidal activity, DNA gyrase inhibitors have recently been identified as active anti-biofilm agents
toward a wide range of pathogenic bacteria, most notably staphylococci (MRSA and MRSE) [15].
Natural products derived from marine sources have been showing promising pharmacological effects
towards a wide array of molecular targets, and their unusual structural diversity provides a crucial
source of lead compounds [16]. We previously reported a number of bioactive metabolites from the
Red Sea-derived sponge Callyspongia siphonella and its associated microorganisms (Table S1) [17–19].
Notably, the two alkaloids, 5- and 6-bromotrisindoline (5-Tris and 6-Tris, respectively; Compounds
1 and 2, Figure 1) together with some phenolic acid derivatives (Compounds 16–27, Table S1) have
shown in vitro antibacterial and antitrypanosomal activities, and cytotoxicity against several tumor
cell lines. Moreover, the alkaloids saccharomonosporine A and convolutamydine F (Compounds 8
and 11) were identified as potent cytotoxic Pim-1 kinase inhibitors. In the present study, as part of
our interest in the discovery of new drug leads from marine-derived natural products, we screened
a small marine natural products library (Compounds 1–36, Table S1) to determine their potential as
antibacterial and antibiofilm agents against staphylococci. Subsequently, the most active compounds
were subjected to in silico inverse virtual screening and in vitro assays to detect their possible molecular
targets. The working outline is depicted in Figure 2.
Figure 1. Some examples of marine-derived indole compounds.
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Figure 2. Outline of the procedure used in this study. SAR: structure–activity relationship.
2. Material and Methods
2.1. Library Construction
All compounds used in the present study (Compounds 1–36, Table S1, Supplementary Materials)
were isolated from the Red Sea-derived sponge Callyspongia siphonella and its associated microorganisms
using multiple chromatographic purification steps and using preparative HPLC (Agilent® 1260 Infinity,
CA, USA) as a final step to obtain these compounds in pure form. The detailed procedure of compounds
extraction and isolation were described previously [17–19]. All chemical structures of the isolated
natural metabolites were determined by analysis of their spectral data (MS and NMR) and comparison
with reported literature. The Bruker Avance III 400 MHz (Bruker AG, Switzerland) and Agilent series
1100 SL (Agilent CO, Santa Clara, CA, USA) were used to acquire the NMR and MS spectra, respectively.
The produced library consisted of 15 indole derivatives, 12 phenolic derivatives, 6 steroidal compounds,
2 triterpenoid compounds, and 1 fatty acid.
2.2. Bacterial Strains
Four human pathogenic bacteria were used in this study, MRSA ATCC33591, Staphylococcus
epidermidis RP62A ATCC12228, Escherichia coli ATCC 259228, and Pseudomonas aeruginosa ATCC9027, in
addition to the non-pathogenic Gram-positive Bacillus subtilis ATCC5230. All the bacterial strains were
maintained at −80 ◦C in 15% glycerol nutrient broth (Oxoid, Milan, Italy).
2.3. Determination of Minimum Inhibitory Concentration (MIC)
The twofold serial dilution approach was applied to determine the MICs of each compound.
Each tested compound was dissolved in DMSO (Sigma, Milan, Italy) to prepare the test solutions.
Many colonies of each tested bacterial strain were inoculated in 10 mL of sterilized Mueller–Hinton
broth (MHB) (Oxoid) and incubated at 37 ◦C for 18–24 h. Subsequently, each bacterial suspension
was adjusted to a final concentration of 100 cfu/mL (OD595 0.13–0.15); then 100 µL of the bacterial
suspension were added in the 96-well cell culture plate (Cellstar®, Greiner Bio-One, Frickenhausen,
Germany), with 0.5 to 128 µM of the test compound solutions. The optical density (595 nm) of every
well was measured using a Multiscan Ex Microplate Reader (Thermo Scientific, Germany). MIC values
were estimated as the lowermost compound concentration that inhibits the bacterial growth after 24 h
of incubation. All data are reported as the mean of three independent experiments.
2.4. Biofilm Assay
The biofilm assay was performed in a 96-well polystyrene plate with a flat bottom according to
the previously described method [2]. S. epidermidis RP62A (OD595 ~ 0.05 in TSB) was incubated in with
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5-Tris and 6-Tris at different concentrations at 37 ◦C for 24 h. OD595 readings were used to estimate the
MICs. Then, the test compound concentration where the lowest OD595 values were measured with
no visible bacterial growth was used to calculate the MIC. After OD595 measurements, the bacterial
cells were discarded by rinsing with sterile PBS. Then, the biofilm cells were fixed by heat at 65 ◦C for
1 h. Plates were subsequently stained with 0.3% crystal violet for 5 min, and then rinsed three times
with sterile double-distilled water and air dried. Finally, OD492 values were used to determine the
magnitude of biofilm inhibition in comparison with the control in test wells. S. epidermidis (ATCC12228)
was used in the experiment as the biofilm negative strain.
2.5. In Vitro Enzymes Assay
DNA gyrase (type II topoisomerase) and topoisomerase IV (Topo IV; ParE) introduce negative
supercoils into DNA, utilizing ATP hydrolysis as a source of energy. They are considered
essential bacterial regulatory enzymes that are absent in eukaryotes. Gyrase subunit B (Gyr-B)
and Topo IV inhibitory activities were determined using the Inspiralis assay kit (Inspiralis®, UK)
on streptavidin-coated 96-well microtiter plates (Thermo Scientific, Germany) according to the
manufacturer’s protocols [20]. The assay measures the ability of the tested compounds to inhibit
the ATPase activity of both Gyr-B and ParE subunits. Briefly, the plates were hydrated with buffer
(20 mM Tris-HCl with pH 7.6, 0.01% w/v BSA, 0.05% v/v Tween 20, 137 mM NaCl) and the biotinylated
oligonucleotide was then immobilized. After the unbound oligonucleotide was washed out, the
enzyme inhibitory assay was performed. The reaction volume of 30 µL in buffer (35 mM Tris ×
HCl with pH 7.5, 4 mM MgCl2, 24 mM KCl, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 6.5 % w/v
glycerol, 0.1 mg/mL albumin) contained 1.5 U of DNA gyrase or Topo IV from S. aureus, 0.75 µg
of relaxed pNO1 plasmid, and 3 µL solution of the inhibitor in 10% DMSO and 0.008% Tween 20.
Subsequently, the reaction solutions were incubated at 37 ◦C for 30 min. At the end of the reaction,
the TF buffer (50 mM NaOAc with pH 5.0, 50 mM NaCl, and 50 mM MgCl2) was added. After
additional incubation for 30 min at room temperature, during which the biotinoligonucleotide-plasmid
triplex was formed, the unbound plasmid was washed off using TF buffer (10 mM Tris HCl with pH
8.0 and 1 mM EDTA). The produced fluorescence was measured using a microplate reader (BioTek
Synergy, excitation: 485 nm, emission: 535 nm, Germany). Initial screening was done at 100 or 10
µM concentration of inhibitors. PK has recently been discovered as an essential hub-protein in the
interactome of MRSA [21]. The PK inhibitory activity of the tested compounds was determined
according to the previously reported method [22]. Shortly, MRSA PK was expressed in pET-28a (+) as
a recombinant protein in E. coli BL-21(DE3) and then purified by using Ni-nitrilotriacetic acid (NTA)
agarose (Quiagen, Inc., Germantown, MD). The PK activity was measured in a continuous assay
coupled to lactate dehydrogenase (LDH) in which the change in absorbance at 340 nm owing to the
oxidation of NADH was measured by the microplate reader. The reaction mixture contained 60 mM
Na+-HEPES (pH 7.5), 5% glycerol, 67 mM KCl, 6.7 mM MgCl2, 0.24 mM NADH, 5.5 units LDH from
rabbit muscle (Sigma Aldrich), 2 mM ADP, and 10 mM PEP in a total volume of 200 mL. The reaction
was initiated by addition of the PK (15 nM). Inhibitors were dissolved in dimethyl sulfoxide (DMSO)
with the final concentration of the solvent never exceeding 1% of the whole assay volume. IC50 values
in both assays were determined using seven concentrations of tested compounds. GraphPad Prism
software was used to calculate the IC50 values. The result was given as the average value of three
independent measurements.
The inhibition constant Ki values for 5-Tris and 6-Tris were determined according to the
manufacturer’s protocols, where the rate of chromogenic substrate hydrolysis, using 2 mM of
the tested enzyme and 0–250 µM of the substrate, was monitored in increasing amounts of inhibitor
(0–10 nM).
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2.6. In Silico Inverse Screening
Well-characterized protein targets, known to be essential for Staphylococcus growth and biofilm
formation, were selected in the Protein Data Bank (PDB) database. Subsequently, these targets were
prepared by removing the water molecules and with the addition of polar hydrogens with Autodock
Tools 1.4.5. Autodock Vina software was used for docking calculations. The grid volumes used for
binding calculations were built using the co-crystallized ligands as a reference (Table S2, Supplementary
Materials). An exhaustiveness of 16 was used for the docking studies. Autodock Vina results were
analyzed with Pymol software.
2.7. Docking Analysis
Staphylococcal Gyr-B and PK crystal structures of the of PDB codes 3g7b and 3T0T, respectively,
were used. Docking experiments were performed using AutoDock Vina docking software.
Such docking engines deal with the receptor as a rigid structure and the ligand as a flexible
structure during its calculations. The co-crystallized ligands were utilized to assign the binding
sites. The ligand-to-binding-site shape matching root mean square threshold was set to 2.0 Å.
The interaction energies were determined using the CFF force field (v.1.02) with 10.0 Å as a non-bonded
cutoff distance and distance-dependent dielectric. Then, 5.0 Å was set as an energy grid extending from
the binding site. The tested compounds were energy-minimized inside the selected binding pocket.
The editing and visualization of the generated binding poses were performed using Pymol software.
2.8. ADME Studies
ADME profiling was measured in silico using the online website “http://www.swissadme.ch/”.
Gastrointestinal (GIT) absorption, blood–brain barrier (BBB), solubility, bioavailability score, and
inhibition of CYP2D6 were selected as ADME descriptors to be calculated.
2.9. Toxicity Profiling
Toxicity profiling was estimated using PreADMET software version 2.0. We screened the
active compounds for carcinogenicity (rat and mouse), mutagenicity, and in vitro hERG inhibition
(cardiotoxicity).
2.10. Statistical Analysis
All the experiments were performed in triplicates. Data were expressed as mean ± SEM. p-Values
< 0.05 were considered as statistically significant. GraphPad Prism® version 6.01 was used for the
statistical analysis of experimental data.
3. Results and Discussion
3.1. Inhibitory Activity Screening
The antibacterial evaluation was performed for our small natural products library (Compounds
1–36, Table S1) in terms of MIC values in µM using standard antibacterial agents (ampicillin and
gentamicin). The results of inhibitory evaluation along with our previous inhibitory reports on other
bacterial strains [19] illustrated that a number of related indole derivatives were the only active
compounds. The brominated oxindole derivatives, 5-bromotrisindoline and 6-bromotrisindoline
(5-Tris and 6-Tris, respectively; Compounds 1 and 2; Table S1) were the most potent metabolites against
Gram-positive bacterial MRSA (MIC 8 and 4 µM, respectively) and B. subtilis (MIC 4 and 4 µM/mL,
respectively). The remaining compounds in this small compound library (phenolics, sterols, and
triterpenes) were inactive against all tested organisms.
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3.2. Antibiofilm Activity
To further evaluate the anti-biofilm activity of 5-Tris and 6-Tris in Gram-positive bacteria, they
were tested at different concentrations against the reference strain S. epidermidis RP62A [2,22]. As shown
in Figure 3, both molecules reduced the growth of an S. epidermidis standard strain in a dose-dependent
manner. We found that 6-Tris has strong antibacterial activity only, where it inhibited the bacterial
growth up to a 5-µM concentration. At lower concentrations, it did not show any effect on both
growth and biofilm formation. On the other hand, 5-Tris revealed lower growth inhibitory activity,
where it inhibited the bacterial growth starting at 20 µM. Moreover, it completely prevented both
standard strains from forming their biofilm at sub-MIC concentrations until 5 µM. We can conclude
from these results that 6-Tris is more potent than its isomer 5-Tris in terms of growth inhibitory activity
(MIC 5 µM and 20 µM, respectively). However, 5-Tris demonstrated a significant antibiofilm activity
with minimum biofilm inhibitory concentration (MBIC) of 5 µM (0.25 MIC). Furthermore, the results
suggested that the position of the bromine atom in 6-position favored the antibacterial activity; however,
the 5- position favored the antibiofilm properties.
Figure 3. Inhibition of biofilm formation and planktonic growth of Staphylococcus epidermidis RP62A by
(A) 5-trisindoline (5-Tris) and (B) 6-trisindoline (6-Tris). OD: Optical Density.
3.3. Structure–Activity Relationship (SAR) Study
From both the antibacterial (Table S1) and antibiofilm results (Figure 3), we can conclude that
the bis-indole is an essential moiety for the antibacterial activity against Gram-positive bacteria.
The addition of an extra oxindole group to form a tris-indole scaffold doubled the antibacterial activity.
Moreover, the presence of a bromine atom significantly increased the activity (4–8 fold). The 5-bromo
derivative 5-Tris was the only active compound as a biofilm inhibitor, indicating that the position of
the bromine in carbon 5 is essential for the antibiofilm activity (Figure 4). Both oxindoles (5-Tris and
6-Tris) may exhibit a narrow spectrum of antibacterial activity (Gram-positive only) as a result of being
neutral compounds. Such molecules together with negatively charged ones were shown to be unable
to cross the protective outer membrane of Gram-negative bacteria [23]. Several previous studies have
illustrated that the positively charged antibiotics, particularly those containing primary amine groups,
accumulate preferentially in Gram-negative bacteria, and hence, during the future development of
these lead compounds, their activity spectrum could be expanded through the addition of a suitable
primary amine group [24].
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Figure 4. Structure–activity relationship of the bioactive indole compounds. PK: pyruvate kinase;
Gyr-B: gyrase subunit B.
3.4. Inverse Virtual Screening
Molecular docking studies were performed for both 5-Tris and 6-Tris to identify potential protein
targets [25]. A number of molecular targets that are common in staphylococci [26,27] were downloaded
from the protein database (PDB) and prepared for the docking experiment. Table 1 arranges the
binding energies in kcal/mol of the two compounds against a list of possible targets. 5-Tris and 6-Tris
showed the highest predicted affinity toward both DNA gyrase subunit B (Gyr B) and pyruvate
kinase (PK) (binding energy of −7.3 and −9.9 kcal/mol for Gyr B, and −8.8 and −6.9 kcal/mol for PK,
respectively) among the docked molecular targets, and hence they were selected for the subsequent
in vitro evaluation.
Table 1. Binding energies (kcal/mol) of 5-Tris and 6-Tris against a number of possible
staphylococcal targets.
Molecular Target Function Mode of Action BindingEnergy (5-Tris)
Binding
Energy (6-Tris)
FtsZ GTPase Cell division −6.3 −6.0
PK Pyruvate kinase Glycolysis −8.8 −6.9
SpsB Signal Peptidase Protein secretion −3.9 −5.0
Isoleucyl-tRNA
synthetase Protein biosynthesis
Protein
modification −5.3 −4.0
Pdf Peptide deformylase Proteinmodification −5.8 −4.9
Peptidyl transferase Protein biosynthesis Proteinmodification 3.9 4.1
rRNA methyltransferase Protein biosynthesis Proteinmodification −4.2 −5.5
Threonyl−tRNA
synthetase Protein biosynthesis
Protein
modification −5.1 −5.2
Gyr A DNA gyrase DNA replication −4.3 −4.8
Gyr B DNA gyrase DNA replication −7.3 −9.9
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Table 1. Cont.
Molecular Target Function Mode of Action BindingEnergy (5-Tris)
Binding
Energy (6-Tris)
ParE Topoisomerase IV DNA replication −5.4 −5.1
Ddl D-alanine ligase Peptidoglycansynthesis −4.1 −4.8
MurB UDP-N-acetylglucosamine-enolpyruvyl reductase
Peptidoglycan
synthesis −6.1 −5.5
PBP2 Peptidoglycan glycosyltransferase
Peptidoglycan
synthesis −3.6 −3.8
DHFR Dihydrofolate reductase Cellular regulation −6.9 −6.1
YycG/YycF Autolysis Cellular regulation −6.7 −6.2
FabF B-ketoacyl-synthase I/II Fatty acid synthesis −3.6 −3.5
FabI Enoly-acyl-carrierprotein reductase Fatty acid synthesis −4.3 −4.2
LigA DNA ligase Stress response −7.0 −6.1
TrxB Thioredoxin reductase Stress response −5.9 −5.0
3.5. In Vitro Assay
From the in silico screening results, we hypothesized that both Gyr B and PK could be potential
targets for 5-Tris and 6-Tris. Inhibition of DNA gyrase subunit A (Gyr A) leads to direct cell death
by trapping the gyrase–DNA complex. On the other hand, inhibition of Gyr B deprives the energy
source needed for DNA replication [14]. Gyr B as a molecular target offers a chance to avoid the
cross-resistance to the well-known Gyr A inhibitors, quinolones. PK is known to be a crucial enzyme
that catalyzes the final glycolysis step, which includes a single phosphoryl group transfer from
phosphoenolpyruvate to ADP, to produce a molecule of pyruvate and ATP [28]. Recently, it was
considered as a “superhub” protein in S. aureus and was found to be essential for staphylococcal growth
and biofilm formation [5–7]. In vitro studies (Table 2) showed 6-Tris to be a potent Gyr B inhibitor (IC50
2.1 ± 0.08 µM) with weak inhibitory activity against PK (IC50 23.2 ± 0.06 µM). On the other side, 5-Tris
exhibited significant inhibitory activity against PK (IC50 6.6 ± 0.05 µM) and lower activity towards
Gyr B (IC50 11.4 ± 0.03 µM) than 6-Tris. Regarding the enzyme affinity of both compounds (Table 2),
5-Tris showed much more affinity towards PK than 6-Tris (Ki: 5.6, 21.9 µM, respectively), but less
affinity towards Gyr-B than 6-Tris (Ki: 7.75, 1.5 µM, respectively). These results clearly illustrated the
role of the bromine position in the selectivity and potency of these inhibitors. Furthermore, they can
suggest that the PK inhibition may have a direct link to the antibiofilm activity that was exhibited
by 5-Tris. Earlier reports supported this point of view and explained the crucial role of PK in the
staphylococcal biofilm formation [6]. To further validate the in silico prediction accuracy we tested
5-Tris and 6-Tris against staphylococcal topoisomerase IV (ParE, Topo IV), which has an essential role
in DNA replication similar to DNA gyrase (Gyr-B), but showed significantly lower predicted binding
affinity towards both 5-Tris and 6-Tris (Table 1). The assay results supported the predicted ones and
revealed that both compounds have weak inhibitory activity against Topo IV, where 5-Tris and 6-Tris
were 3 times and 12 times more active against Gyr-B than Topo IV, respectively (IC50 33.17 ± 0.04 and
25.14 ± 0.03 µM, respectively).
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Table 2. MRSA DNA gyrase-B, pyruvate kinase, and topoisomerase IV inhibitions as IC50 and inhibition
constant Ki values.
Tested Compound
IC50 (Ki) ± S.D. µM a
DNA Gyrase Pyruvate Kinase Topoisomerase IV
5-Tris 11.4 ± 0.03 (Ki: 7.75 ± 0.05) 6.6 ± 0.05 (Ki: 5.6 ± 0.02) 33.17 ± 0.04
6-Tris 2.1 ± 0.08 (Ki: 1. 5 ± 0.03) 23.2 ± 0.06 (Ki: 21.9 ± 0.04) 25.14 ± 0.03
Novobiocin 0.12 ± 0.01 * 0.22 ± 0.01
a Values are the mean of three independent experiments. *—not determined.
3.6. In Silico Binding Mode Study
The potential binding modes of 5-Tris and 6-Tris with both Gyr B and PK were analyzed by
docking their active binding sites. MRSA Gyr B and PK of PDB code (3g7b and 3T0T) were chosen for
the docking experiments due to their optimum resolutions (2.3 Å and 3.1 Å) and are co-crystallized with
their inhibitors. The spheres around the co-crystallized inhibitors were assigned as binding sites for
docking. Both 5-Tris and 6-Tris showed convergent docking poses (Figure 5) and were comparable to
the co-crystallized Gyr-B inhibitor [29]. The indole nitrogen in only one indole group of the two 5-Tris
indoles is hydrogen-bonded to the carbonyl oxygen of ASP-81, and the benzene moiety of the same
indole is buried within a hydrophobic pocket of ILE-51, ILE-175, and LEU-103. Moreover, the carbonyl
oxygen of the oxindole is hydrogen-bonded to the main chain carbonyl of GLY-85. The co-crystallized
ligand forms a similar hydrogen bond with ASP-81 and a further two hydrogen bonds with a different
amino acid residue, ASN-54. Alternatively, the existence of bromine in position 6 in 6-Tris directed the
whole molecule toward a better binding mode and better fitting inside the binding pocket of Gyr-B
(Figure 5). Both indole groups of the molecule became able to interact with the binding site’s residues,
where the nitrogen of the first one is similarly hydrogen-bonded to the carbonyl and hydroxyl oxygen
of ASP-81, and the nitrogen of the second indole is hydrogen-bonded to GLY-85. Furthermore, both
the amidic hydrogen and the carbonyl oxygen of the oxindole moiety are tightly anchored inside the
binding cavity through four hydrogen bonds with ASP-57 and GLU-58, respectively, and through
the reported one with ASN-54. Such a strong interaction can explain the superior activity of 6-Tris
(IC50 2.1 ± 0.08 µM) over 5-Tris (IC50 11.4 ± 0.03 µM) and the co-crystallized ligand. On the other
hand, both 5-Tris and 6-Tris showed different binding modes in the PK active site. The co-crystalized
PK inhibitor [21,30] is perfectly fitted inside the pocket formed between the enzyme’s subunits A
and B (Figure 6). This binding mode is stabilized by six main hydrogen bonds with SER-362A,
SER-362B, ASN-369B, and HIS-365A (A and B correspond to PK subunits). These residues provide
target selectivity because they are conserved only in the staphylococcal PK and not found in the human
PK. Herein, 5-Tris shows convergent binding mode to the co-crystallized PK inhibitor, where it anchors
in one side of the PK active site (Figure 6) through three hydrogen bonds with SER-362A and HIS-365A,
similarly to the co-crystalized ligand, and an additional hydrogen bond with THR-353A. Moreover,
the 5-bromo group is further stabilized 5-Tris binding through the strong hydrophobic interaction with
the hinge of LEU-368B, LYS-341B and LEU-344B (Figure 6). Regarding 6-Tris, again, the position of the
bromine atom shows a vital role in the interaction with the active site. The bromine in 6-Tris directed
the whole molecule to interact with the other side of the binding pocket (Figure 6), where the carbonyl
oxygen of the oxindole moiety forms three weak hydrogen bonds (distance > 4 Å) with HIS-365B,
THR-348B, and THR-353B, in addition to another weak hydrogen bond between the nitrogen of one
indole moiety with SER-362B, and thus this weak interaction in comparison to 5-Tris explains the
inferior activity against PK (5-Tris IC50 = 6.6 ± 0.05 µM; 6-Tris IC50 = 23.2 ± 0.06 µM).
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Figure 5. Docking study of 5-Tris (A,B) and 6-Tris (C,D) within the active site of multidrug-resistant
Staphylococcus aureus (MRSA) Gyr-B. The key binding interactions of the Gyr-B co-crystallized ligand [29]
are shown in (E,F). The amino acid side chains are depicted in (A,C,E) for clarification.
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Figure 6. Docking study of 5-Tris (A,B) and 6-Tris (C,D) within the active site of MRSA PK. The key
binding interactions of the PK co-crystallized ligand [21] are shown in (E,F). The amino acid side chains
are depicted in (A,C,E) for clarification.
3.7. In Silico ADME/Tox Prediction
The majority of drug candidates fail during the clinical development due to inappropriate
ADME/Tox profiles, and hence, the virtual screening should not be limited to predicting and optimizing
binding affinity of a given drug molecule, but the pharmacokinetic parameters should also be involved
as significant filters to further optimize selected lead molecules into drug candidates, and reduce failure
rates during clinical trials. The predicted ADMET/Tox profiles of 5-Tris and 6-Tris were calculated
using the online software SwissADME and preADMET. Generally, both compounds showed excellent
drug-like properties, high oral absorption, high bioavailability, and moderate toxicity (Tables 3 and 4).
Such predicted toxicity (e.g., the mutagenic and carcinogenic characteristics) of both compounds
should be taken into consideration during their development, so that the possible future derivatives
will be more efficient as therapeutic agents with minimal toxicity profiles.
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Table 3. Predicted ADME profiles of 5-Tris and 6-Tris.
Compound Lipinski a BBB b GIT Absorption c Solubility d CYP2D6 e Bioavailability Score f
5-Tris Yes Yes High Moderate Yes 0.55
6-Tris Yes Yes High Moderate Yes 0.55
a Predicts if the compound has a drug-like properties (follows the Lipinski rule of five); b Predicts the ability of
the compound to penetrate the blood–brain barrier (BBB) according to the yolk of the boiled egg; c Predicts the
gastrointestinal absorption according to the white of the boiled egg; d Predicts the solubility of each compound in
water; e Predicts the cytochrome P450 inhibition; f Predicts the bioavailability score.
Table 4. Predicted toxicity profile of 5-Tris and 6-Tris.
Compound 5-Tris 6-Tris
Mutagenicity Mutagen Mutagen
Carcinogenicity (mouse) Positive Positive
Carcinogenicity (rat) Negative Negative
hERG inhibition (cardiotoxicity) Ambiguous Moderate Risk
4. Conclusions
Currently, much research is being directed toward the discovery of novel antimicrobial molecules
that can act as biofilm inhibitors. Marine invertebrates are considered a prolific source of diverse
pharmacologically active metabolites with different ecological potentials. In the present investigation,
we prepared a small library of bioactive metabolites that were isolated from the marine-derived sponge
C. siphonella and its associated symbiotic microbes. This library was screened against a panel of
standard bacterial pathogens (two Gram-positive and two Gram-negative strains), including MRSA.
Based on the obtained results, both 5-Tris and 6-Tris were the most active compounds and subsequently
were selected for antibiofilm activity evaluation against a standard strain (S. epidermidis). Only 5-Tris
was able to inhibit the ability of S. epidermidis to form its biofilm up to 5 µM. On the other hand, 6-Tris
showed strong bacterial growth activity without biofilm inhibition. The antibacterial and antibiofilm
results enabled us to construct a structure–activity relationship for the bis-indole scaffold. To investigate
the possible molecular targets that may mediate these biological effects, we screened both 5-Tris and
6-Tris against a panel of selected targets (inverse virtual screening). This innovative in silico approach
allowed us to prioritize Gyr-B and PK as the most promising candidates depending on the binding
energy of each target protein. The in vitro assay thereafter revealed that 6-Tris is a potent Gyr-B
inhibitor with weak activity against PK; however, 5-Tris is considered a dual inhibitor of both enzymes
with a moderate potency. Additionally, the in silico ADME predictions suggested that both 5-Tris
and 6-Tris have drug-like properties and could be promising leads for further evaluation. Further
development and in vivo studies will be of interest to improve the potency and to assess the efficacy as
well as the possible toxicity of these molecules.
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